Highlights and Quick Summary
- Equity Repurchase (Common, Net) for the quarter ending June 30, 2021 was $29.7 Million (a 4.58% increase compared to previous quarter)
- Annual Equity Repurchase (Common, Net) for 2021 was $29.2 Million (a 200.6% increase from previous year)
- Annual Equity Repurchase (Common, Net) for 2020 was $9.71 Million (a 2742.04% increase from previous year)
- Annual Equity Repurchase (Common, Net) for 2019 was $342 Thousand (a -98.83% decrease from previous year)
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Equity Repurchase (Common, Net) of Biofrontera AG Sponsored ADR
Most recent Equity Repurchase (Common, Net)of BFAGY including historical data for past 10 years.Interactive Chart of Equity Repurchase (Common, Net) of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | $29.72 | $29.18 |
| 2020 | – | – | – | – | $9.71 |
| 2019 | – | – | – | – | $0.34 |
| 2018 | – | – | – | $28.42 | $29.09 |
| 2017 | – | – | – | – | $-0.73 |
| 2016 | – | – | – | – | $27.13 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic